Rheumatoid arthritis<unk>  citrate is approved for medical use in the United States with an indication "to treat adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to, or who are intolerant of, methotrexate." In the European Union, in combination with methotrexate,<unk>  citrate is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adults who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs. It can be given as monotherapy in case of intolerance to methotrexate or when treatment with MTX is inappropriate. Ulcerative colitis In May 2018, the FDA approved<unk>  citrate "for the treatment of adult patients in the U.S. with moderately to severely active ulcerative colitis."<unk>  citrate is the first oral JAK inhibitor approved for use in chronic ulcerative colitis.
Tofacitinib
Ocrelizumab
Belatacept
Etanercept
Ibalizumab
Sarilumab
Theralizumab
Atezolizumab